Cytokinetics Future Growth

Future criteria checks 0/6

Cytokinetics's earnings is forecast to decline at an annual rate of 23.1% and its revenue is expected to decline at 46.6% annually. EPS and ROE are forecast to grow 26.9% and -44.7% each year respectively.

Key information

23.1%

Earnings growth rate

26.9%

EPS growth rate

Biotechs earnings growth	14.4%
Revenue growth rate	46.6%
Future return on equity	-44.7%
Analyst coverage	Good
Last updated	20 Mar 2023

Recent future growth updates

Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 20

Recent updates

Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

Mar 03

Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 20

Newsflash: Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Revenue Forecasts

Dec 15

Cytokinetics: Surprise Adcomm For Omecamtiv Causing Concern

Oct 17

Cytokinetics gets monitoring panel's nod to continue phase 3 trial of ALS drug reldesemtiv

Oct 10

Cytokinetics (NASDAQ:CYTK) Has Debt But No Earnings; Should You Worry?

Aug 23

Cytokinetics GAAP EPS of -$0.23 beats by $0.81, revenue of $88.97M beats by $85.24M

Aug 04

Cytokinetics: Emerging Leader In Heart Failure Drugs, But Let It Truly Emerge First

Jun 27

What You Need To Know About The Cytokinetics, Incorporated (NASDAQ:CYTK) Analyst Downgrade Today

May 09

Is Cytokinetics (NASDAQ:CYTK) Using Debt Sensibly?

Apr 25

Cytokinetics: A Brighter Future In Muscle Biology

Apr 11

Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Just Cut Their EPS Forecasts Substantially

Mar 03

Broker Revenue Forecasts For Cytokinetics, Incorporated (NASDAQ:CYTK) Are Surging Higher

Jan 09

Cytokinetics: Biotech That Should Be On Your Radar With Several Catalysts In 2022

Jan 08

Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Dec 07

Circling Back On Cytokinetics

Oct 03

Earnings and Revenue Growth Forecasts

NasdaqGS:CYTK - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	258	-373	-334	-364	10
12/31/2024	60	-465	-363	-424	13
12/31/2023	46	-429	-336	-357	14
12/31/2019	27	-122	-94	-91	N/A
9/30/2019	31	-118	-86	-84	N/A
6/30/2019	36	-110	-97	-96	N/A
3/31/2019	35	-105	-99	-98	N/A
12/31/2018	32	-106	-102	-101	N/A
9/30/2018	22	-120	-114	-113	N/A
6/30/2018	18	-131	-108	-106	N/A
3/31/2018	14	-132	-112	-111	N/A
12/31/2017	13	-128	-105	-102	N/A
9/30/2017	47	-80	-3	0	N/A
6/30/2017	99	-14	11	14	N/A
3/31/2017	102	3	31	34	N/A
12/31/2016	106	16	35	37	N/A
9/30/2016	83	0	N/A	-51	N/A
6/30/2016	32	-42	N/A	-49	N/A
3/31/2016	33	-41	N/A	-47	N/A

Cytokinetics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price

Price target decreased to US$62.00

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 532%

Recent updates

CEO, President & Director notifies of intention to sell stock

Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

Full year 2022 earnings: EPS and revenues miss analyst expectations

VP & Chief Accounting Officer notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q4, 2022 Results on Mar 01, 2023

Senior VP & CFO notifies of intention to sell stock

Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Newsflash: Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Revenue Forecasts

Cytokinetics, Incorporated Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

Price target decreased to US$62.00

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136

CEO, President & Director exercised options and sold US$296k worth of stock

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

VP & Chief Accounting Officer recently sold US$85k worth of stock

Consensus forecasts updated

Cytokinetics, Incorporated Presents New Data at the American Heart Association Scientific Sessions 2022

CEO, President & Director notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Cytokinetics, Incorporated to Report Q3, 2022 Results on Nov 03, 2022

Cytokinetics: Surprise Adcomm For Omecamtiv Causing Concern

Insider exercised options and sold US$810k worth of stock

Cytokinetics, Incorporated Announces Continuation of COURAGE-ALS Following First Interim Analysis

Cytokinetics gets monitoring panel's nod to continue phase 3 trial of ALS drug reldesemtiv

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

Independent Director exercised options and sold US$1.3m worth of stock

Cytokinetics (NASDAQ:CYTK) Has Debt But No Earnings; Should You Worry?

CEO, President & Director notifies of intention to sell stock

Consensus revenue estimates increase by 532%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics' Completed ALS Clinical Trials

CEO, President & Director exercised options and sold US$333k worth of stock

Cytokinetics GAAP EPS of -$0.23 beats by $0.81, revenue of $88.97M beats by $85.24M

Cytokinetics, Incorporated to Report Q2, 2022 Results on Aug 04, 2022

CEO, President & Director exercised options and sold US$364k worth of stock

Cytokinetics: Emerging Leader In Heart Failure Drugs, But Let It Truly Emerge First

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Provides Update on New Drug Application

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

Cytokinetics, Incorporated Announces Additional Data from Redwood-HCM Presented At the American Society of Echocardiography 33Rd Annual Scientific Sessions

CEO, President & Director notifies of intention to sell stock

Consensus revenue estimates fall by 34%

What You Need To Know About The Cytokinetics, Incorporated (NASDAQ:CYTK) Analyst Downgrade Today

CEO, President & Director notifies of intention to sell stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Is Cytokinetics (NASDAQ:CYTK) Using Debt Sensibly?

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q1, 2022 Results on May 04, 2022

Cytokinetics, Incorporated Announces Retirement of Mark A. Schlossberg as Senior Vice President, Legal, General Counsel and Secretary, Effective May 13, 2022

Cytokinetics: A Brighter Future In Muscle Biology

Cytokinetics, Incorporated Announces Changes to Board of Directors

Senior VP & CFO exercised options and sold US$718k worth of stock

Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session

Independent Director exercised options and sold US$267k worth of stock

Cytokinetics, Incorporated Announces Cohort 4 of REDWOOD-HCM is Open to Enrollment

Cytokinetics, Incorporated Announces Cohort 4 of REDWOOD-HCM is Open to Enrollment

Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Just Cut Their EPS Forecasts Substantially

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cytokinetics, Incorporated Provides Earnings Guidance for the Year 2022

Cytokinetics, Incorporated Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Announces Resignation of Robert M. Califf as Member of the Board of Directors

Cytokinetics, Incorporated Announces Topline Results From METEORIC-HF

CEO, President & Director exercised options and sold US$259k worth of stock